Naair will report to CEO Shreehas Tambe and joins the Executive Leadership Team; Seema Ahuja to transition to a new role in ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Naair will lead Biocon Biologics' global brand and corporate communications strategy as part of its executive team, reporting ...

Biocon Biologics on Wednesday announced the appointment of Deepali Naair as Global Head Brand & Corporate Communications, ...

Biocon's subsidiary, Biocon Biologics, has introduced Nepexto, a biosimilar to Enbrel (Etanercept), in Australia for treating ...

The shares of biopharmaceutical firm Biocon fell as much as 2.04 per cent in Tuesday's trading session, figuring among top ...

Nepexto will be promoted by Generic Health, BBL's local partner and a leading provider of high-quality generic prescription, ...

Shares of Biocon experienced a decline of 2.01% to Rs 386.70 in Tuesday's session, with the stock figuring among the top ...

Biocon’s Yesintek, launched in February, does the same job for just under $3,000 per dose—roughly 90% less than Stelara. In all, Mazumdar-Shaw’s company has debuted nine biosimilar drugs, ...

Biocon Biologics, a subsidiary of Biocon, has introduced Nepexto, a biosimilar to Enbrel, in the Australian market for ...

With over three decades of experience across India, ASEAN, and Australia, Deepali Naair brings deep expertise in brand ...

Bengaluru: Biocon Biologics Limited, a fully integrated global biosimilars company and a subsidiary of Biocon Limited, has ...